Cellectar Biosciences (CLRB) Scheduled to Post Earnings on Monday

Cellectar Biosciences (NASDAQ:CLRB) is scheduled to be announcing its earnings results before the market opens on Monday, November 18th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Cellectar Biosciences (NASDAQ:CLRB) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter. On average, analysts expect Cellectar Biosciences to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cellectar Biosciences Stock Down 7.5 %

Shares of CLRB opened at $1.86 on Friday. The business has a 50-day simple moving average of $2.07 and a two-hundred day simple moving average of $2.44. Cellectar Biosciences has a 52 week low of $1.82 and a 52 week high of $4.45. The stock has a market cap of $75.46 million, a price-to-earnings ratio of -0.74 and a beta of 1.00.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on CLRB. Oppenheimer reissued an “outperform” rating and issued a $14.00 target price on shares of Cellectar Biosciences in a report on Friday, October 11th. StockNews.com raised shares of Cellectar Biosciences to a “sell” rating in a research note on Thursday, September 26th.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.